title: Latency period after preterm premature rupture of membranes: a comparison of ampicillin with and without sulbactam.
abstract: OBJECTIVE
  To compare ampicillin with and without sulbactam with respect to the effect on the latency period after preterm premature rupture of membranes (PROM).
  
  
  METHODS
  Patients with PROM at 25-35 weeks' gestation were offered participation in a randomized blinded trial comparing ampicillin-sulbactam with ampicillin. Evaluations for cervical pathogens were performed on admission and patients were followed-up with daily maternal and fetal evaluation. Maternal and neonatal outcomes were analyzed using indicated techniques.
  
  
  RESULTS
  Fifty-three women were studied, with 25 receiving ampicillin-sulbactam and 28 receiving ampicillin. The ampicillin-sulbactam group had a significantly longer latency period (433 +/- 625 versus 143 +/- 165 hours, P = .03) and significantly fewer neonatal complications (five versus 20, P < .001). Although no neonatal infectious complications were observed in sulbactam-treated cases, there were four cases of neonatal sepsis and two of neonatal pneumonia in the ampicillin group. Also, significantly more neonates in the ampicillin group required prolonged oxygen and ventilatory support. There was no significant difference in maternal morbidity.
  
  
  CONCLUSIONS
  In our population with preterm PROM, a broad-spectrum antibiotic that provides anaerobic coverage appears to extend latency and decrease neonatal morbidity without increasing adverse maternal outcome.
authors.affiliation: Department of Obstetrics and Gynecology, Louisana State University School of Medicine, Shreveport, USA.
authors.forename: D F
authors.initials: DF
authors.lastname: Lewis
authors.forename: M T
authors.initials: MT
authors.lastname: Fontenot
authors.forename: G G
authors.initials: GG
authors.lastname: Brooks
authors.forename: R
authors.initials: R
authors.lastname: Wise
authors.forename: M B
authors.initials: MB
authors.lastname: Perkins
authors.forename: A R
authors.initials: AR
authors.lastname: Heymann
mesh_terms: D000328:Adult; D000667:Ampicillin / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000150:complications / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D011014:Pneumonia / Q000382:microbiology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000382:microbiology; D011256:Pregnancy Outcome; D018805:Sepsis / Q000382:microbiology; D013407:Sulbactam / Q000627:therapeutic use*; D002577:Uterine Cervical Diseases / Q000150:complications / Q000382:microbiology
chemical_list: D004338:Drug Combinations; D000667:Ampicillin; D013407:Sulbactam